Home/All releases
All press releases
Company news, research breakthroughs, and major announcements across industries.
Showing 451–460 of 489
All press releases
Energy
Siemens to digitalize one of Europe’s largest renewable hydrogen projects
Siemens and Galp will digitalize GalpH2Park in Sines, Portugal, a 100 MW renewable hydrogen plant expected to produce up to 15,000 tons a year.
October 8, 2026Health|Pfizer’s TUKYSA Regimen
Pfizer’s TUKYSA Regimen Receives FDA Approval as Front-Line Maintenance Treatment for HER2+ Metastatic Breast Cancer
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved TUKYSA® (tucatinib) in combination with trastuzumab and pertuzumab for the maintenance treatment of adults with unrese…
October 7, 2026 · 12:57 PM
Multimedia|JCB
JCB Launches Premium Card Issuing Initiative for Affluent Customers in ASEAN Under Strategic Comprehensive Partnership with MUFG Bank
October 6, 2026 · 3:00 PM
Energy
Chevron to divest Hess Midstream and DJ Basin crude midstream interests
Chevron will transfer its Hess Midstream stake and DJ Basin crude midstream assets for improved Bakken contract terms and $200 million in cash, a deal it expects to cut Bakken midstream costs by about half.
October 6, 2026
Automotive|Toyota
Toyota launches the new hydrogen fuel-cell route bus Sora
Toyota launched the new Sora fuel-cell route bus, developed with Isuzu. A more efficient hydrogen system extends its range to more than 300 km.
October 5, 2026Health
Pfizer’s LITFULO Significantly Improved Facial and Total Body Repigmentation in Patients with Nonsegmental Vitiligo
Pfizer Inc. (NYSE: PFE) today presented results from two Phase 3 trials evaluating the efficacy and safety of LITFULO® (ritlecitinib) as a once-daily oral treatment across a wide range of disease extent. In the two studi…
October 2, 2026 · 11:15 AM
Multimedia
Fujitsu to showcase technologies for a resilient society at CEATEC 2026
October 1, 2026 · 1:32 PMHealth
Pfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study
Pfizer Inc. (NYSE: PFE) today presented detailed results from an ongoing Phase 2 study investigating tilrekimig (PF-07275315) in adults with moderate-to-severe atopic dermatitis (AD). The study met its primary endpoint,…
October 1, 2026 · 2:30 AMConsumer|Chase
Chase introduces the IHG One Rewards Premier Select Credit Card
Chase and IHG Hotels & Resorts introduced a new Premier Select card with richer travel benefits, and updated earning, Free Night, and status rewards across the rest of the IHG card portfolio.
October 1, 2026
Multimedia
